Cargando…
Antibody-based cancer therapy
Over the past 25 years, antibody therapeutics have emerged as clinically and commercially successful pharmaceuticals, rapidly approaching 100 Food and Drug Administration approvals with combined annual global sales exceeding $100 billion. Nearly half of the marketed antibody therapeutics are used in...
Autores principales: | Goydel, Rebecca S., Rader, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357052/ https://www.ncbi.nlm.nih.gov/pubmed/33947958 http://dx.doi.org/10.1038/s41388-021-01811-8 |
Ejemplares similares
-
Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates
por: Nanna, Alex R., et al.
Publicado: (2017) -
From rabbit antibody repertoires to rabbit monoclonal antibodies
por: Weber, Justus, et al.
Publicado: (2017) -
Site-Specific Antibody–Drug Conjugates in Triple Variable Domain Fab Format
por: Hwang, Dobeen, et al.
Publicado: (2020) -
Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates
por: Adhikari, Ajeeth, et al.
Publicado: (2021) -
Improving the Serum Stability of Site-Specific Antibody
Conjugates with Sulfone Linkers
por: Patterson, James T., et al.
Publicado: (2014)